基本信息

职称：青年研究员
电话：021-51630574
邮箱：lingchenchina@fudan.edu.cn
地址：复旦大学生命科学学院 C125室

男，1986年出生，博士，青年研究员。2003-2007年就读复旦大学生命科学学院生物科学专业，2007-2011年在美国佛罗里达大学医学院小儿科作研究生，2011年获理学博士学位。2011-2016年在美国佛罗里达大学医学院小儿科任教，先后任助博士后、研究助理教授（2012）。2016－现在，在复旦大学生命科学学院遗传学任青年研究员，从事遗传疾病与肿瘤基因治疗、病毒学等研究工作。

血友病、地中海贫血症等遗传疾病的基因治疗。肝癌的基因治疗。腺相关病毒基础生物学研究。

2016年上海市东方学者特聘教授；2011年美国霍华德休斯研究院-佛罗里达大学优秀博士生奖；

1. Ling C*, Bhukhai K*, Yin Z*, Tan M, Yoder M, Leboulch P#, Payen E# and Srivastava A#. (2016) High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing. Scientific Reports. Accepted.
2. Ling C#, Li B, Ma W, Srivastava A. (2016) Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses. Human Gene Therapy Methods. 27(4):143-9.
3. Sayroo R, Nolasco D, Yin Z, Cortes C. Y, Pandya M, Ling C# & Aslanidi G#. (2015) Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Therapy. 23(1):18-25. PMID: 26270885.
4. Li S*,  Ling C*, Zhong L*, Li M, Su Q, He R, Tang Q, Greiner L. D, Shultz D. L, Brehm A. M, Flotte R. T, Mueller C,  Srivastava A#, & GaoG#. (2015) Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Molecular Therapy. 23(12):1867-76. PMID: 26403887; PMCID: PMC4700112. *Co-first author. 
5. Li B*, Ma W*, Ling C*, Vliet V. K, Huang L, Agbandje-McKenna M, Srivastava A#, and Aslanidi V. G#. (2015) Site-directed mutagenesis of surface-exposed lysine residues leads to improved transduction by AAV2, but not AAV8 vectors in murine hepatocytes in vivo. Human Gene Therapy Methods. 26(6):211-220. PMID: 26421998; PMCID: PMC4677520. *Co-first author.
6. Ling C, Wang Y, Lu Y, Wang L, Jayandharan G, Aslanidi V. G, Li B, Cheng B, Ma W, Lentz T, Ling CQ, Xiao X, Samulski R. J, Muzyczka N & Srivastava A#. (2015) The Adeno-Associated Virus Genome Packaging Puzzle. Journal of Molecular and Genetic Medicine. 9:175. doi:10.4172/1747-0862.1000175.
7. Ling C*, Wang Y*, Feng YL, Zhang YN, Li J, Hu XR, Wang LN, Zhong MF, Zhai XF, Zolotukhin I, Srivastava A# & Ling CQ#. (2015) Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions. Journal of Integrative Medicine, 13(5):341-6. PMID: 26343106. PMID: 26343106. *Co-first author.
8. Pandya M, Britt K, Hoffman B, Ling C# & Aslanidi G#. (2015) Reprogramming immune response with capsid-optimized AAV6 vectors for immunotherapy of cancer. Journal of Immunotherapy, 38(7):292-8. PMID: 26261893; PMCID: PMC4535186.
9. Wang L, Yin Z, Wang Y, Lu Y, Zhang D, Srivastava A, Ling CQ, Aslanidi GV# & Ling C#. (2015) Productive life cycle of the adeno-associated virus 2 in the complete absence of a conventional polyadenylation signal. Journal of General Virology, 96(9):2780-7. PMID: 26297494; PMCID: PMC4635500.
10. Ling C#*, Wang Y*, Lu Y, Wang LN, Jayandharan G, Aslanidi V. G, Li B, Cheng B, Ma W, Lentz T, Ling CQ, Xiao X, Samulski R. J, Muzyczka N & Srivastava A#. (2015) Enhanced transgene expression from recombinant single-stranded AAV vectors in human cell lines in vitro and in murine hepatocytes in vivo. Journal of Virology, 89(2):952-61. PMID: 25355884; PMCID: PMC4300666. *Co-first author. 
11. Ling C#*, Wang Y*, Zhang YH, Ejjigani A, Yin Zifei, Lu Y, Wang LN, Wang M, Li Jun, Hu Z, Aslanidi GV, Zhong Li, Gao G, Srivastava A# & Ling CQ#. (2014) Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Human Gene Therapy, 25(12):1023-34. PMID: 25296041; PMCID: PMC4270149.  *Co-first author.
12. Zhang YH, Wang Y, Yusufali A, Ashby F, Zhang D, Yin ZF, Aslanidi V. G, Srivastava A, Ling CQ# & Ling C#. (2014) Cytotoxic Genes from Traditional Chinese Medicine Inhibit Tumor Growth both in vitro and in vivo. Journal of Integrative Medicine, 12(6):483-94. PMID: 25412666.
13. Wang L, Wang Y, Yin Z, Zhang Y, Aslanidi G, Srivastava A, Ling CQ# and Ling C#. (2014) Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. Journal of Integrative Medicine, 12(1):20-34. PMID: 24461592.
14. Cheng B*, Ling C*, Dai Y, Lu Y, Glushakova L.G, Gee S.W.Y., McGoogan K.E., Aslanidi G.V., Park M, Stacpoole P.W., Siemann D, Liu C, Srivastava A# & Ling CQ# (2012). Development of optimized AAV3 serotype vectors: Mechanism of high-efficiency transduction of human liver cancer cells. Gene Therapy, 19(4): 375-84. PMID: 21776025; PMCID: PMC3519243. *Co-first author.
15. Wang Y*, Ling C*, Song L, Wang L, Aslanidi G, Tan M, Ling CQ# & Srivastava A#. (2012). Limitations of encapsidation of recombinant scAAV2 genomes in different serotype capsids and their quantitation. Human Gene Therapy Methods, 23(4):225-33. PMID: 22966785; PMCID: PMC4015078. *Co-first author.
16. Ling C, Lu Y, Cheng B, McGoogan KE, Gee SW, Ma W, Li B, Aslanidi GV & Srivastava A#. (2011). High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors. Journal of Visualized Experiments, 22(49). PMID: 21445055; PMCID: PMC3197307.
17. Ling C, Lu Y, Kelsi JK, Jayandharan GR, Li B, Ma W, Cheng B, Gee SW, McGoogan KE, Govindasamy L, Zhong L, Agbandje-McKenna M & Srivastava A#. (2010). Human Hepatocyte Growth Factor Receptor is a Cellular Co-Receptor for AAV3. Hum Gene Therapy, 21(12), 1741-1747. PMID: 20545554; PMCID: PMC2999576.
18. Ling C#. (2004) Effects of Purslane Herb on Stress Ability of Aging Mice Induced by D-galactose. Zhong Xi Yi Jie He Xue Bao. 2(5), 361-363. PMID: 15383260.